How did you possibly miss Google back when it was $100?
You remember that, don't you? The stock went public in August 2004, and BOOM -- that's all she wrote. What were you thinking?
My good friend hindsight, a clear 20-20, is telling me you seriously dropped the ball. You'd have multiplied your money by a factor of five in less than four years. I'd also wager that you're looking at last year's offering of Visa or MercadoLibre with a similar kind of regretful feeling.
Don't despair -- there is a silver lining.
Forget the hype
These two companies have performed remarkably well thus far. In the real world, though, most new offerings just don't live up to the hype. Ask shareholders of Entropic Communications
When you're getting into a newly issued stock, you're really doing two things that smart investors don't like to do:
- You're investing in a company with lots of attention behind it. The likely consequence of excess excitement is a seriously questionable price tag.
- You're sending money to an unproven public entity. The company may have done fantastically when it was private, but everything comes under a little more scrutiny when it's public. Management may also not know how to properly allocate all of the money that comes in from the public offering and could blow it on wasteful projects. In short, there's rarely a track record at newly public companies ... and track records matter.
Buffett says "No"
Needless to say, plenty of top investors don't find this situation intriguing. Warren Buffett is one. In Lawrence Cunningham's book The Essays of Warren Buffett (a book I highly recommend reading), the Oracle spells it out quite clearly:
The new-issue market ... is ruled by controlling stockholders and corporations, who can usually select the timing of offerings or, if the market looks unfavorable, can avoid an offering altogether. Understandably, these sellers are not going to offer any bargains, either by way of a public offering or in a negotiated transaction: It's rare you'll find X for 1/2X here.
He's not just arbitrarily avoiding these IPOs. Studies prove that IPOs and recent offering just don't demonstrate long-term overperformance. According to one study from the University of Chicago's Graduate School of Business, IPOs experience brief flare-ups in price during the first three months of going public (thanks to the structure of certain regulatory and corporate events) but otherwise fail to show any kind of abnormal performance in the long run.
The proof's in the pudding ...
And we've seen this time and time again. What happened to investors who got in "early" on Vonage
I'm not suggesting you always avoid new offerings. After all, at some point, all of my favorite businesses -- Morningstar
You must find value
Even if you're able to get your hands on a great business, you've won only half of the battle. You should be looking for great businesses at great prices. That's the trick. Buffett's crafty investments in companies such as Costco
Before you buy, scrutinize new, hyped-up issues through the lens of a value hunter. What are you buying? And how much is it going to cost you?
Seemingly cheap situations aren't likely when you're sorting the companies making exciting headlines. But the values are rampant in the quiet sectors, the otherwise neglected slices of the stock market where great investors like Buffett thrive.
Discover where you can thrive
If this kind of approach sounds good to you, and you need a bit of a boost, I encourage you to check out our Motley Fool Inside Value investing service, where advisor Philip Durell and his team specialize in finding great business at great prices.
You can see their top picks for new money as well as all of their research and recommendations by joining the service free for 30 days.
Fool analyst Nick Kapur is always looking for the greatest companies, and he owns shares of Morningstar and American Express, as does The Motley Fool. Morningstar and Costco are Motley Fool Stock Advisor recommendations. American Express is an Inside Value recommendation. The Fool has a disclosure policy.